Actavis CEO: We may be big, but we don't want to be Big Pharma

Big Pharma or "growth pharma"? Actavis ($ACT) CEO Brent Saunders is aiming for the latter. Though his company is expected to rank among the industry's top 10 after closing its Allergan ($AGN) buy later this year, Saunders says Actavis won't act like a Big Pharma. What's the difference? He has some ideas. Report

Suggested Articles

After showing Nucala could cut the rates of flares for hypereosinophilic syndrome, GSK is planning regulatory filings in 2020.

Mylan and Pfizer's Upjohn have a name for their pending merger: Viatris. Heard that before? So has Mylan, which owns a subsidiary with the same name.

Both IL-17A inhibitors have rolled out data showing they work in non-radiographic axial spondyloarthritis.